- Merck plans over $70 billion in U.S. investments to boost production and innovation.
- JANUVIA, JANUMET, and JANUMET XR will be offered at 70% off through a direct-to-patient program.
- Enlicitide, a potential oral PCSK9 inhibitor, aims to address cardiovascular needs pending FDA approval.
- Merck delays Section 232 tariffs for three years to support U.S. manufacturing investments.
Investment and Innovation
Merck has committed over $70 billion to enhance U.S. production and innovation. This includes more than $12 billion in capital expenditures and significant investments in R&D, supporting tens of thousands of jobs. New facilities in Virginia, Kansas, and Delaware will create 1,200 full-time jobs and support 15,000 construction jobs.
Drug Pricing and Access
Merck will offer key drugs like JANUVIA, JANUMET, and JANUMET XR at approximately 70% off through a direct-to-patient program. This initiative aims to make these medications more affordable for eligible American patients.
Enlicitide Development
Enlicitide, a novel oral PCSK9 inhibitor, is designed to lower LDL cholesterol and address cardiovascular needs. Pending FDA approval, it will be made widely available as an affordable option for American patients.
Tariff Agreement
Merck has reached an understanding with the U.S. Department of Commerce to delay Section 232 tariffs for three years. This agreement supports Merck's efforts to reshore manufacturing and invest in U.S. facilities.
